Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 57237-086

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 57237-086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

The text describes a figure (Figure 1) that shows a Kaplan-Meier plot on the probability of achieving a headache response (no or mild pain) after treatment with rizatriptan benzoate or placebo. The plot displays the estimated probability of response over time, and the averages shown are based on pooled data from 4 placebo-controlled outpatient trials (Studies 1, 2, 3, and 4). The patients who took additional treatment or did not achieve headache response before 2 hours were not considered.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

This text provides a figure showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over 24 hours following the initial dose of study treatment in pooled studies 1, 2, 3, and 4. The Kaplan-Meier plot is based on data obtained in four placebo-controlled outpatient clinical trials. Patients who did not use additional treatments were censored at 24 hours, and remedication was not allowed within two hours post-dose.*

FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

The text describes the estimated probability of achieving an initial headache response with Rizatriptan Benzoate Orally Disintegrating Tablets by 2 hours in Pooled Studies 5 and 6. It shows a Kaptan-Meier graph of the probability of obtaining headache response with the medication or placebo over time. The text mentions that the displayed data is based on two placebo-controlled outpatient trials providing evidence of efficacy. Patients who did not achieve headache response within 2 hours were likely given additional treatment.*

FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 5 And 6‡‡ (Rizatriptan Fig4)

This is a figure showing the Estimated Probability of Patients Taking a Second Dose of Rizatriptan Benzoate Orally Disintegrating Tablets or Other Medication for Migraines Over the 24 Hours Following the Initial Dose of Study Treatment in Pooled Studies 5 and 6. The plot is a Kaplan-Mier plot based on data obtained in 2 placebo-controlled outpatient clinical trials (Studies 3 and 6). Patients not using additional treatments were censored at 24 hours. The plot includes both patients who had a headache response at 2 hours and those who had no response to the initial dose. However, some parts of the text are not readable due to errors.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

The image shows a graph titled "Figure 5" representing data obtained from "Study 7". It displays the percentage of patients who reported no headache pain 2 hours after taking a dose of either Rizatriptan Benzoate OD Tablets or placebo. The X-axis denotes the hours post Stage 2 dose, while the Y-axis denotes the percentage of patients. The text mentions specific percentages and markings on the graph related to both treatments.*

FDA Label Image

Package Label-principal Display Panel (5 mg Unit-Dose Pack (18 Tablets))

The text describes a medication package of orally disintegrating tablets called Rizatriptan Benzoate. The box contains 18 tablets divided into three blister cards, and each tablet is equivalent to 5 mg of Rizatriptan Benzoate. The package has a pharmacy label and was distributed by Rising Health, LLC. The text also contains some unreadable characters.*

FDA Label Image

Package Label-principal Display Panel (10 mg Unit-Dose Pack (18 Tablets))

This text appears to be a label of Rizatriptan Benzoate orally disintegrating tablets with instructions related to the contents of each tablet. It also mentions the ingredients and associated warning for users who have phenylketonuria. The label contains relevant information about the number of tablets and their distribution information.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.